The Option Value of New Therapeutics
University of Chicago - Law School; University of Chicago Pritzker School of Medicine; Resources for the Future; National Bureau of Economic Research (NBER)
University of Virginia - Statistics Department
October 25, 2004
Drug control agencies such as the U.S. FDA typically decide whether to approve a new therapeutic based upon the average treatment effect of the new therapeutic. Unless the mean effect of the new therapeutic is greater than a conventional treatment or placebo, the agency will not permits the new therapeutic's use. In the presence of ex post heterogeneity in treatment effects, however, average treatment effects fail to account for the full value a new therapeutic. Even if the new therapeutic is no better than placebo for the average patient, there may be a number of patients who are better off under the new therapeutic than any conventional treatment. If this is the case, prohibiting use of the new therapeutic imposes a welfare loss on these patients. This paper examines the major influences on this loss, which we call the option value of the new therapeutic. It proposes simple estimators for this value and calculates the option value of drugs examined in the Cardiac Arrhythmia Suppression Trial (CAST) I. Finally, the paper examines drawbacks of relying on option value to make drug approval decisions.
Number of Pages in PDF File: 19
Keywords: food and drug law, averate treatment effects, option, pharmaceuticals, cardiology
JEL Classification: C40, C93, I12, K32working papers series
Date posted: November 12, 2004
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo3 in 0.453 seconds